[
  {
    "type": "scholar",
    "query": "semaglutide real-world effectiveness obesity non-diabetic 2023..2025",
    "saved_at": "2025-10-24T07:39:32.487634+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-semaglutide-real-world-effectiveness-48a4f0ac__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 10,
      "crossref": 0,
      "total": 10
    },
    "preview": "A Google search for 'semaglutide real-world effectiveness obesity non-diabetic 2023..2025' found 10 results:\n\n## Web Results\n1. [THU283 Oral Semaglutide, Effectiveness, Safety And Tolerability In Real Life: A Short-term Retrospective Observational Study](https://www.semanticscholar.org/paper/48fdb11"
  },
  {
    "type": "scholar",
    "query": "tirzepatide cardiovascular safety RWD cohort",
    "saved_at": "2025-10-24T07:39:34.048732+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-tirzepatide-cardiovascular-safety-rw-b5f2e26c__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 0,
      "crossref": 0,
      "total": 0
    },
    "preview": "Google search Timeout, return None, Please try again later."
  },
  {
    "type": "scholar",
    "query": "GLP-1 discontinuation reasons adherence persistence MPR",
    "saved_at": "2025-10-24T07:39:35.392811+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-glp-1-discontinuation-reasons-adhere-ceee4f75__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 10,
      "crossref": 0,
      "total": 10
    },
    "preview": "A Google search for 'GLP-1 discontinuation reasons adherence persistence MPR' found 10 results:\n\n## Web Results\n1. [Persistence and Adherence to GLP-1 RA treatment in Type 2 Diabetes Mellitus: a Nationwide registry study](https://www.semanticscholar.org/paper/884047fc61d8bee16237fc30a7e9c552f738569d"
  },
  {
    "type": "scholar",
    "query": "semaglutide major adverse cardiovascular events real-world",
    "saved_at": "2025-10-24T07:39:37.947224+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-semaglutide-major-adverse-cardiovasc-5665e890__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 10,
      "crossref": 0,
      "total": 10
    },
    "preview": "A Google search for 'semaglutide major adverse cardiovascular events real-world' found 10 results:\n\n## Web Results\n1. [Comparative Efficacy of Tirzepatide, Liraglutide, and Semaglutide in Reduction of Risk of Major Adverse Cardiovascular Events in Patients with Obstructive Sleep Apnea and Type 2 Dia"
  },
  {
    "type": "scholar",
    "query": "EMA SmPC semaglutide pdf site:ema.europa.eu",
    "saved_at": "2025-10-24T07:39:39.784714+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-ema-smpc-semaglutide-pdf-site-ema-eu-7f854791__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 0,
      "crossref": 10,
      "total": 10
    },
    "preview": "A Google search for 'EMA SmPC semaglutide pdf site:ema.europa.eu' found 10 results:\n\n## Web Results\n1. [EMA safety committee to review link between semaglutide and rare eye condition](https://doi.org/10.1211/pj.2025.1.344423)\nDate published: 2025\nSource: Crossref\n\n\n2. [Einführung: Neues Europa — alt"
  },
  {
    "type": "scholar",
    "query": "FDA label tirzepatide pdf site:fda.gov",
    "saved_at": "2025-10-24T07:39:45.090554+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-fda-label-tirzepatide-pdf-site-fda-g-7017faf5__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 10,
      "crossref": 0,
      "total": 10
    },
    "preview": "A Google search for 'FDA label tirzepatide pdf site:fda.gov' found 10 results:\n\n## Web Results\n1. [A real-world disproportionality analysis of tirzepatide-related adverse events based on the FDA Adverse Event Reporting System (FAERS) database](https://www.semanticscholar.org/paper/a5aed14686c27f688b"
  },
  {
    "type": "scholar",
    "query": "NICE technology appraisal semaglutide obesity TA972 pdf",
    "saved_at": "2025-10-24T07:39:46.306400+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-nice-technology-appraisal-semaglutid-6df6227c__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 2,
      "crossref": 8,
      "total": 10
    },
    "preview": "A Google search for 'NICE technology appraisal semaglutide obesity TA972 pdf' found 10 results:\n\n## Web Results\n1. [critique of semaglutide (Wegovy®) for obesity management NICE technology appraisal TA875](https://www.semanticscholar.org/paper/ae13b6b91785191883cdf3ac70f6a3207d6edf15)\nDate published"
  },
  {
    "type": "scholar",
    "query": "MHRA drug safety update semaglutide 2024",
    "saved_at": "2025-10-24T07:39:47.517760+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-mhra-drug-safety-update-semaglutide--b8501a06__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 10,
      "crossref": 0,
      "total": 10
    },
    "preview": "A Google search for 'MHRA drug safety update semaglutide 2024' found 10 results:\n\n## Web Results\n1. [MHRA Drug Safety Update - topical steroids.](https://www.semanticscholar.org/paper/1e28d020b0ebf4a5ec8288f9a7d29cd1de728e77)\nDate published: 2024\nSource: Semantic Scholar\n\n\n2. [MHRA issues further up"
  },
  {
    "type": "scholar",
    "query": "HAS avis semaglutide obésité pdf site:has-sante.fr",
    "saved_at": "2025-10-24T07:39:48.299194+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-has-avis-semaglutide-ob-sit-pdf-site-57d72c60__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 0,
      "crossref": 10,
      "total": 10
    },
    "preview": "A Google search for 'HAS avis semaglutide obésité pdf site:has-sante.fr' found 10 results:\n\n## Web Results\n1. [[RETRACTED] Diaetoxil Avis Fr: Acheter {Diaetoxil Avis France} &amp;amp; Utiliser Diaetoxyl Avis Ou Detoxil Avis! v1](https://doi.org/10.17504/protocols.io.6qpvr656bvmk/v1)\nDate published: "
  },
  {
    "type": "scholar",
    "query": "IQWiG Nutzenbewertung semaglutid pdf site:iqwig.de",
    "saved_at": "2025-10-24T07:39:49.416463+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-iqwig-nutzenbewertung-semaglutid-pdf-622c4880__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 0,
      "crossref": 10,
      "total": 10
    },
    "preview": "A Google search for 'IQWiG Nutzenbewertung semaglutid pdf site:iqwig.de' found 10 results:\n\n## Web Results\n1. [IQWiG lässt Hypoglykämiegefahr außer Acht](http://link.springer.com/content/pdf/10.1007/s15034-013-0200-3.pdf)\nDate published: 2013\nSource: Crossref\n\n\n2. [Frühe Nutzenbewertung - IQWiG-Guta"
  },
  {
    "type": "scholar",
    "query": "CADTH semaglutide obesity reimbursement pdf site:cadth.ca",
    "saved_at": "2025-10-24T07:39:49.887081+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-cadth-semaglutide-obesity-reimbursem-9c461182__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 0,
      "crossref": 10,
      "total": 10
    },
    "preview": "A Google search for 'CADTH semaglutide obesity reimbursement pdf site:cadth.ca' found 10 results:\n\n## Web Results\n1. [Semaglutide (Wegovy)](https://canjhealthtechnol.ca/index.php/cjht/article/download/SR0725r/SR0725r)\nDate published: 2022\nSource: Crossref\n\n<jats:p>&#x0D;\nCADTH reimbursement reviews "
  },
  {
    "type": "scholar",
    "query": "G-BA Richtlinie GLP-1 Fettleibigkeit pdf",
    "saved_at": "2025-10-24T07:39:51.670274+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-g-ba-richtlinie-glp-1-fettleibigkeit-029953cf__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 2,
      "crossref": 8,
      "total": 10
    },
    "preview": "A Google search for 'G-BA Richtlinie GLP-1 Fettleibigkeit pdf' found 10 results:\n\n## Web Results\n1. [Stellungnahme zum Beratungsverfahren des G-BA über die Richtlinie zur Erprobung der „Endoskopischen duodenalen Thermoablation bei Diabetes mellitus Typ 2“](https://www.semanticscholar.org/paper/5bc8d"
  },
  {
    "type": "scholar",
    "query": "tirzepatide cost-effectiveness UK NICE submission",
    "saved_at": "2025-10-24T07:39:53.403581+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-tirzepatide-cost-effectiveness-uk-ni-f97a0294__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 10,
      "crossref": 0,
      "total": 10
    },
    "preview": "A Google search for 'tirzepatide cost-effectiveness UK NICE submission' found 10 results:\n\n## Web Results\n1. [EE306 Comparison of Methods for Extrapolation of Drug Survival of Biologics in Psoriasis NICE Submission Cost-Effectiveness Analyses](https://www.semanticscholar.org/paper/b1c4aaa104fb931652"
  },
  {
    "type": "scholar",
    "query": "semaglutide ICER obesity US payer perspective",
    "saved_at": "2025-10-24T07:39:54.876743+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-semaglutide-icer-obesity-us-payer-pe-f30fc799__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 10,
      "crossref": 0,
      "total": 10
    },
    "preview": "A Google search for 'semaglutide ICER obesity US payer perspective' found 10 results:\n\n## Web Results\n1. [Cost-effectiveness analysis of elacestrant versus standard endocrine therapy for second-/third-line treatment of patients with HR+/HER2- advanced or metastatic breast cancer: a US payer perspect"
  },
  {
    "type": "scholar",
    "query": "GLP-1 budget impact model EU 2024",
    "saved_at": "2025-10-24T07:39:55.734134+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-glp-1-budget-impact-model-eu-2024-9e20f97b__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 10,
      "crossref": 0,
      "total": 10
    },
    "preview": "A Google search for 'GLP-1 budget impact model EU 2024' found 10 results:\n\n## Web Results\n1. [S918 The Impact of GLP-1 Receptor Agonists on Upper and Lower GI Endoscopy: A Systematic Review and Meta-Analysis](https://www.semanticscholar.org/paper/49f93a8d2585b65d450961013cf2fca495b58483)\nDate publis"
  },
  {
    "type": "scholar",
    "query": "AHRQ safety signal semaglutide gastrointestinal events",
    "saved_at": "2025-10-24T07:39:57.705486+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-ahrq-safety-signal-semaglutide-gastr-1854b7d7__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 10,
      "crossref": 0,
      "total": 10
    },
    "preview": "A Google search for 'AHRQ safety signal semaglutide gastrointestinal events' found 10 results:\n\n## Web Results\n1. [Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of rand"
  },
  {
    "type": "scholar",
    "query": "semaglutide real-world weight loss 2.4mg adherence persistence",
    "saved_at": "2025-10-24T07:39:59.326339+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-semaglutide-real-world-weight-loss-2-d8a85626__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 0,
      "crossref": 0,
      "total": 0
    },
    "preview": "Google search Timeout, return None, Please try again later."
  },
  {
    "type": "scholar",
    "query": "tirzepatide discontinuation dose 5mg vs 10mg registry",
    "saved_at": "2025-10-24T07:40:00.970616+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-tirzepatide-discontinuation-dose-5mg-27616907__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 10,
      "crossref": 0,
      "total": 10
    },
    "preview": "A Google search for 'tirzepatide discontinuation dose 5mg vs 10mg registry' found 10 results:\n\n## Web Results\n1. [A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?](https://www.semanticscholar.org/paper/ea81186ae78f627aa0fcf4fbe72e28"
  },
  {
    "type": "scholar",
    "query": "GLP-1 RWD comorbidities cardiovascular risk stratification",
    "saved_at": "2025-10-24T07:40:02.638086+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-glp-1-rwd-comorbidities-cardiovascul-2ab24227__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 0,
      "crossref": 0,
      "total": 0
    },
    "preview": "Google search Timeout, return None, Please try again later."
  },
  {
    "type": "scholar",
    "query": "on-treatment analysis semaglutide MACE",
    "saved_at": "2025-10-24T07:40:02.985158+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-on-treatment-analysis-semaglutide-ma-dcbf9670__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 10,
      "crossref": 0,
      "total": 10
    },
    "preview": "A Google search for 'on-treatment analysis semaglutide MACE' found 10 results:\n\n## Web Results\n1. [Glycemic Control, Weight Management, Cardiovascular Safety, and Cost-Effectiveness of Semaglutide for Patients with Type 2 Diabetes Mellitus: A Rapid Review and Meta-analysis of Real-World Studies](htt"
  },
  {
    "type": "scholar",
    "query": "FDA Adverse Event Reporting System semaglutide pancreatitis",
    "saved_at": "2025-10-24T07:40:04.765468+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-fda-adverse-event-reporting-system-s-e8feb530__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 10,
      "crossref": 0,
      "total": 10
    },
    "preview": "A Google search for 'FDA Adverse Event Reporting System semaglutide pancreatitis' found 10 results:\n\n## Web Results\n1. [Abstract 4142273: Pharmacosurveillance study of FDA Adverse Event Reporting System (FAERS) events of Tirzepatide and Semaglutide](https://www.semanticscholar.org/paper/28cc17e56f36"
  },
  {
    "type": "scholar",
    "query": "EMA pharmacovigilance GLP-1 suicidal ideation signal",
    "saved_at": "2025-10-24T07:40:05.455303+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-ema-pharmacovigilance-glp-1-suicidal-430f96f6__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 10,
      "crossref": 0,
      "total": 10
    },
    "preview": "A Google search for 'EMA pharmacovigilance GLP-1 suicidal ideation signal' found 10 results:\n\n## Web Results\n1. [Association of GLP‐1 Receptor Agonists With Risk of Suicidal Ideation and Behaviour: A Systematic Review and Meta‐Analysis](https://www.semanticscholar.org/paper/38c41fd35c21e223b889da394"
  },
  {
    "type": "scholar",
    "query": "real-world severe hypoglycemia semaglutide non-diabetic",
    "saved_at": "2025-10-24T07:40:06.098249+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-real-world-severe-hypoglycemia-semag-f11d77db__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 10,
      "crossref": 0,
      "total": 10
    },
    "preview": "A Google search for 'real-world severe hypoglycemia semaglutide non-diabetic' found 10 results:\n\n## Web Results\n1. [Real-World Use of Control-IQ Technology Is Associated with a Lower Rate of Severe Hypoglycemia and Diabetic Ketoacidosis Than Historical Data: Results of the Control-IQ Observational ("
  },
  {
    "type": "scholar",
    "query": "tirzepatide gallbladder events cohort study",
    "saved_at": "2025-10-24T07:40:08.291877+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-tirzepatide-gallbladder-events-cohor-b349f8e0__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 10,
      "crossref": 0,
      "total": 10
    },
    "preview": "A Google search for 'tirzepatide gallbladder events cohort study' found 10 results:\n\n## Web Results\n1. [Dipeptidyl Peptidase-4 Inhibitors and the Risk of Gallbladder and Bile Duct Disease Among Patients with Type 2 Diabetes: A Population-Based Cohort Study.](https://www.semanticscholar.org/paper/80b"
  },
  {
    "type": "scholar",
    "query": "NHS England GLP-1 prescribing guidelines 2024",
    "saved_at": "2025-10-24T07:40:09.438022+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-nhs-england-glp-1-prescribing-guidel-fa539f54__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 10,
      "crossref": 0,
      "total": 10
    },
    "preview": "A Google search for 'NHS England GLP-1 prescribing guidelines 2024' found 10 results:\n\n## Web Results\n1. [Healthcare workers' views on antibiotic prescribing and stewardship during the COVID-19 pandemic at an NHS Foundation Trust in England: a cross-sectional survey](https://www.semanticscholar.org/"
  },
  {
    "type": "scholar",
    "query": "AHA scientific statement GLP-1 cardiovascular outcomes",
    "saved_at": "2025-10-24T07:40:11.090046+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-aha-scientific-statement-glp-1-cardi-62568f88__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 0,
      "crossref": 0,
      "total": 0
    },
    "preview": "Google search Timeout, return None, Please try again later."
  },
  {
    "type": "scholar",
    "query": "ESC position paper obesity pharmacotherapy 2023",
    "saved_at": "2025-10-24T07:40:12.773227+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-esc-position-paper-obesity-pharmacot-7a8d4c5f__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 10,
      "crossref": 0,
      "total": 10
    },
    "preview": "A Google search for 'ESC position paper obesity pharmacotherapy 2023' found 10 results:\n\n## Web Results\n1. [STRUGGLE FOR. Italian-Polish-Spanish-Uzbek-Vietnamese Expert Forum Position Paper 2023 for better control of classical modifiable risk factors in clinical practice](https://www.semanticscholar"
  },
  {
    "type": "scholar",
    "query": "ADA Standards of Care semaglutide indication",
    "saved_at": "2025-10-24T07:40:14.149679+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-ada-standards-of-care-semaglutide-in-e38542d4__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 10,
      "crossref": 0,
      "total": 10
    },
    "preview": "A Google search for 'ADA Standards of Care semaglutide indication' found 10 results:\n\n## Web Results\n1. [Standards of Specialized Diabetes Care / Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 11th Edition](https://www.semanticscholar.org/paper/db6dc976a55b8f4e6d3220cab3aee6e40a6067d3)\nDate pu"
  },
  {
    "type": "scholar",
    "query": "semaglutide real-world effectiveness age subgroup analysis",
    "saved_at": "2025-10-24T07:40:15.749035+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-semaglutide-real-world-effectiveness-172514e5__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 0,
      "crossref": 0,
      "total": 0
    },
    "preview": "Google search Timeout, return None, Please try again later."
  },
  {
    "type": "scholar",
    "query": "tirzepatide discontinuation renal impairment",
    "saved_at": "2025-10-24T07:40:17.413342+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-tirzepatide-discontinuation-renal-im-74ba6723__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 0,
      "crossref": 0,
      "total": 0
    },
    "preview": "Google search Timeout, return None, Please try again later."
  },
  {
    "type": "scholar",
    "query": "propensity score matching GLP-1 RCT vs real-world",
    "saved_at": "2025-10-24T07:40:19.268127+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-propensity-score-matching-glp-1-rct--3c7fe217__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 10,
      "crossref": 0,
      "total": 10
    },
    "preview": "A Google search for 'propensity score matching GLP-1 RCT vs real-world' found 10 results:\n\n## Web Results\n1. [737-P: Acute Healthcare Utilization, Mortality, and Cardiovascular Events following GLP-1-RA Initiation by Patients with Advanced Chronic Kidney Disease—A Real-World Comparative Study](https"
  },
  {
    "type": "scholar",
    "query": "instrumental variable analysis GLP-1 adherence",
    "saved_at": "2025-10-24T07:40:22.157847+00:00",
    "md_file": "/home/arnav/Desktop/Pythoncode/DeepResearch/inference/workingDocuments/2/scholar-instrumental-variable-analysis-glp-1-5574d721__scholar.md",
    "status": "ok",
    "counts": {
      "semanticscholar": 10,
      "crossref": 0,
      "total": 10
    },
    "preview": "A Google search for 'instrumental variable analysis GLP-1 adherence' found 10 results:\n\n## Web Results\n1. [530-P: Evaluating the Role of a Digital Health Platform in Supporting GLP-1 Adherence and Sustained Outcomes Post-discontinuation](https://www.semanticscholar.org/paper/15fe8e96ac551f3b8dd25349"
  },
  {
    "url": "https://www.ema.europa.eu/en/documents/product-information/ozempic-epar-product-information_en.pdf",
    "saved_at": "2025-10-24T07:42:25.149257+00:00",
    "goal": "Extract exact quotes regarding indications, dosing, efficacy endpoints, cardiovascular outcomes, discontinuation rates, adverse events (particularly GI, gallbladder, pancreatitis), and special populations. Identify all numerical data with units, confidence intervals, and sample sizes from clinical trials referenced in these documents. Pay special attention to sections on 'Clinical Trials Experience,' 'Adverse Reactions,' 'Use in Specific Populations,' and 'Clinical Pharmacology.'",
    "raw_file": null,
    "extracted_file": null,
    "summary_file": null,
    "status": "fallback",
    "http_status": null,
    "content_type": null,
    "final_url": "https://www.ema.europa.eu/en/documents/product-information/ozempic-epar-product-information_en.pdf"
  },
  {
    "url": "https://www.ema.europa.eu/en/documents/product-information/wegovy-epar-product-information_en.pdf",
    "saved_at": "2025-10-24T07:42:28.391124+00:00",
    "goal": "Extract exact quotes regarding indications, dosing, efficacy endpoints, cardiovascular outcomes, discontinuation rates, adverse events (particularly GI, gallbladder, pancreatitis), and special populations. Identify all numerical data with units, confidence intervals, and sample sizes from clinical trials referenced in these documents. Pay special attention to sections on 'Clinical Trials Experience,' 'Adverse Reactions,' 'Use in Specific Populations,' and 'Clinical Pharmacology.'",
    "raw_file": null,
    "extracted_file": null,
    "summary_file": null,
    "status": "fallback",
    "http_status": null,
    "content_type": null,
    "final_url": "https://www.ema.europa.eu/en/documents/product-information/wegovy-epar-product-information_en.pdf"
  },
  {
    "url": "https://www.fda.gov/media/155314/download",
    "saved_at": "2025-10-24T07:42:28.940899+00:00",
    "goal": "Extract exact quotes regarding indications, dosing, efficacy endpoints, cardiovascular outcomes, discontinuation rates, adverse events (particularly GI, gallbladder, pancreatitis), and special populations. Identify all numerical data with units, confidence intervals, and sample sizes from clinical trials referenced in these documents. Pay special attention to sections on 'Clinical Trials Experience,' 'Adverse Reactions,' 'Use in Specific Populations,' and 'Clinical Pharmacology.'",
    "raw_file": null,
    "extracted_file": null,
    "summary_file": null,
    "status": "fallback",
    "http_status": null,
    "content_type": null,
    "final_url": "https://www.fda.gov/media/155314/download"
  },
  {
    "url": "https://www.cadth.ca/sites/default/files/cdr/rapid-response/RR2306-Semaglutide-Wegovy-Obesity-English.pdf",
    "saved_at": "2025-10-24T07:43:33.056436+00:00",
    "goal": "Extract NICE/CADTH recommendations verbatim, including specific criteria for use, population restrictions, cost-effectiveness thresholds, ICERs, and key evidence gaps. Identify all quantitative data on weight loss, cardiovascular benefits, discontinuation rates, and safety concerns that informed their decisions. Note any differences between UK and Canadian assessments.",
    "raw_file": null,
    "extracted_file": null,
    "summary_file": null,
    "status": "fallback",
    "http_status": null,
    "content_type": null,
    "final_url": "https://www.cadth.ca/sites/default/files/cdr/rapid-response/RR2306-Semaglutide-Wegovy-Obesity-English.pdf"
  },
  {
    "url": "https://www.sciencedirect.com/science/article/pii/S000293432400447X",
    "saved_at": "2025-10-24T07:47:44.847123+00:00",
    "goal": "Extract cardiovascular outcome data specifically: definition of MACE used, event rates in treatment vs control groups, hazard ratios with CIs, absolute risk reductions, number needed to treat, subgroup analyses by age/sex/comorbidity, and sensitivity analyses. Note any discrepancies between studies in cardiovascular findings.",
    "raw_file": null,
    "extracted_file": null,
    "summary_file": null,
    "status": "fallback",
    "http_status": null,
    "content_type": null,
    "final_url": "https://www.sciencedirect.com/science/article/pii/S000293432400447X"
  },
  {
    "url": "https://academic.oup.com/jcem/article/109/7/e3105/7684818",
    "saved_at": "2025-10-24T07:47:45.508177+00:00",
    "goal": "Extract cardiovascular outcome data specifically: definition of MACE used, event rates in treatment vs control groups, hazard ratios with CIs, absolute risk reductions, number needed to treat, subgroup analyses by age/sex/comorbidity, and sensitivity analyses. Note any discrepancies between studies in cardiovascular findings.",
    "raw_file": null,
    "extracted_file": null,
    "summary_file": null,
    "status": "fallback",
    "http_status": null,
    "content_type": null,
    "final_url": "https://academic.oup.com/jcem/article/109/7/e3105/7684818"
  },
  {
    "url": "https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.068140",
    "saved_at": "2025-10-24T07:47:45.713472+00:00",
    "goal": "Extract cardiovascular outcome data specifically: definition of MACE used, event rates in treatment vs control groups, hazard ratios with CIs, absolute risk reductions, number needed to treat, subgroup analyses by age/sex/comorbidity, and sensitivity analyses. Note any discrepancies between studies in cardiovascular findings.",
    "raw_file": null,
    "extracted_file": null,
    "summary_file": null,
    "status": "fallback",
    "http_status": null,
    "content_type": null,
    "final_url": "https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.068140"
  },
  {
    "url": "https://www.sciencedirect.com/science/article/pii/S000293432400447X",
    "saved_at": "2025-10-24T07:47:45.999182+00:00",
    "goal": "Extract detailed discontinuation and adherence data: overall rates at 6/12/18 months, reasons for discontinuation (categorized), adherence metrics (PDC, MPR), predictors of discontinuation (demographic, clinical), impact of discontinuation on weight regain and clinical outcomes, and comparison between different GLP-1 formulations.",
    "raw_file": null,
    "extracted_file": null,
    "summary_file": null,
    "status": "fallback",
    "http_status": null,
    "content_type": null,
    "final_url": "https://www.sciencedirect.com/science/article/pii/S000293432400447X"
  },
  {
    "url": "https://www.sciencedirect.com/science/article/pii/S2213176724000524",
    "saved_at": "2025-10-24T07:47:46.284862+00:00",
    "goal": "Extract detailed discontinuation and adherence data: overall rates at 6/12/18 months, reasons for discontinuation (categorized), adherence metrics (PDC, MPR), predictors of discontinuation (demographic, clinical), impact of discontinuation on weight regain and clinical outcomes, and comparison between different GLP-1 formulations.",
    "raw_file": null,
    "extracted_file": null,
    "summary_file": null,
    "status": "fallback",
    "http_status": null,
    "content_type": null,
    "final_url": "https://www.sciencedirect.com/science/article/pii/S2213176724000524"
  },
  {
    "url": "https://www.sciencedirect.com/science/article/pii/S2213176724000524",
    "saved_at": "2025-10-24T07:47:46.622754+00:00",
    "goal": "Extract detailed discontinuation and adherence data: overall rates at 6/12/18 months, reasons for discontinuation (categorized), adherence metrics (PDC, MPR), predictors of discontinuation (demographic, clinical), impact of discontinuation on weight regain and clinical outcomes, and comparison between different GLP-1 formulations.",
    "raw_file": null,
    "extracted_file": null,
    "summary_file": null,
    "status": "fallback",
    "http_status": null,
    "content_type": null,
    "final_url": "https://www.sciencedirect.com/science/article/pii/S2213176724000524"
  },
  {
    "url": "https://www.sciencedirect.com/science/article/pii/S000293432400447X",
    "saved_at": "2025-10-24T07:47:47.018565+00:00",
    "goal": "Extract comprehensive safety profile: incidence rates of common AEs (nausea, vomiting, diarrhea), serious AEs, gallbladder events (cholelithiasis, cholecystitis), pancreatitis, suicidal ideation signals, renal events, with exact percentages, CIs, and statistical comparisons to control groups. Note any dose-response relationships and time-to-onset patterns.",
    "raw_file": null,
    "extracted_file": null,
    "summary_file": null,
    "status": "fallback",
    "http_status": null,
    "content_type": null,
    "final_url": "https://www.sciencedirect.com/science/article/pii/S000293432400447X"
  },
  {
    "url": "https://www.sciencedirect.com/science/article/pii/S2213176724000524",
    "saved_at": "2025-10-24T07:47:47.288793+00:00",
    "goal": "Extract comprehensive safety profile: incidence rates of common AEs (nausea, vomiting, diarrhea), serious AEs, gallbladder events (cholelithiasis, cholecystitis), pancreatitis, suicidal ideation signals, renal events, with exact percentages, CIs, and statistical comparisons to control groups. Note any dose-response relationships and time-to-onset patterns.",
    "raw_file": null,
    "extracted_file": null,
    "summary_file": null,
    "status": "fallback",
    "http_status": null,
    "content_type": null,
    "final_url": "https://www.sciencedirect.com/science/article/pii/S2213176724000524"
  },
  {
    "url": "https://www.sciencedirect.com/science/article/pii/S2213176724000524",
    "saved_at": "2025-10-24T07:47:47.632616+00:00",
    "goal": "Extract comprehensive safety profile: incidence rates of common AEs (nausea, vomiting, diarrhea), serious AEs, gallbladder events (cholelithiasis, cholecystitis), pancreatitis, suicidal ideation signals, renal events, with exact percentages, CIs, and statistical comparisons to control groups. Note any dose-response relationships and time-to-onset patterns.",
    "raw_file": null,
    "extracted_file": null,
    "summary_file": null,
    "status": "fallback",
    "http_status": null,
    "content_type": null,
    "final_url": "https://www.sciencedirect.com/science/article/pii/S2213176724000524"
  },
  {
    "url": "https://www.sciencedirect.com/science/article/pii/S000293432400447X",
    "saved_at": "2025-10-24T07:47:47.869814+00:00",
    "goal": "Extract cost-effectiveness data: ICERs with CIs, quality-adjusted life years gained, budget impact analyses, threshold values used by different agencies (NICE, IQWiG, CADTH), and sensitivity analyses showing key drivers of cost-effectiveness. Compare across different healthcare systems.",
    "raw_file": null,
    "extracted_file": null,
    "summary_file": null,
    "status": "fallback",
    "http_status": null,
    "content_type": null,
    "final_url": "https://www.sciencedirect.com/science/article/pii/S000293432400447X"
  },
  {
    "url": "https://www.sciencedirect.com/science/article/pii/S2213176724000524",
    "saved_at": "2025-10-24T07:47:48.239504+00:00",
    "goal": "Extract cost-effectiveness data: ICERs with CIs, quality-adjusted life years gained, budget impact analyses, threshold values used by different agencies (NICE, IQWiG, CADTH), and sensitivity analyses showing key drivers of cost-effectiveness. Compare across different healthcare systems.",
    "raw_file": null,
    "extracted_file": null,
    "summary_file": null,
    "status": "fallback",
    "http_status": null,
    "content_type": null,
    "final_url": "https://www.sciencedirect.com/science/article/pii/S2213176724000524"
  },
  {
    "url": "https://www.sciencedirect.com/science/article/pii/S2213176724000524",
    "saved_at": "2025-10-24T07:47:48.486492+00:00",
    "goal": "Extract cost-effectiveness data: ICERs with CIs, quality-adjusted life years gained, budget impact analyses, threshold values used by different agencies (NICE, IQWiG, CADTH), and sensitivity analyses showing key drivers of cost-effectiveness. Compare across different healthcare systems.",
    "raw_file": null,
    "extracted_file": null,
    "summary_file": null,
    "status": "fallback",
    "http_status": null,
    "content_type": null,
    "final_url": "https://www.sciencedirect.com/science/article/pii/S2213176724000524"
  },
  {
    "url": "https://www.sciencedirect.com/science/article/pii/S000293432400447X",
    "saved_at": "2025-10-24T07:47:48.746445+00:00",
    "goal": "Extract evidence on real-world implementation challenges: payer policies, access restrictions, patient eligibility criteria, provider prescribing patterns, and barriers to optimal use. Identify specific gaps between clinical trial populations and real-world users.",
    "raw_file": null,
    "extracted_file": null,
    "summary_file": null,
    "status": "fallback",
    "http_status": null,
    "content_type": null,
    "final_url": "https://www.sciencedirect.com/science/article/pii/S000293432400447X"
  },
  {
    "url": "https://www.sciencedirect.com/science/article/pii/S2213176724000524",
    "saved_at": "2025-10-24T07:47:48.973890+00:00",
    "goal": "Extract evidence on real-world implementation challenges: payer policies, access restrictions, patient eligibility criteria, provider prescribing patterns, and barriers to optimal use. Identify specific gaps between clinical trial populations and real-world users.",
    "raw_file": null,
    "extracted_file": null,
    "summary_file": null,
    "status": "fallback",
    "http_status": null,
    "content_type": null,
    "final_url": "https://www.sciencedirect.com/science/article/pii/S2213176724000524"
  },
  {
    "url": "https://www.sciencedirect.com/science/article/pii/S2213176724000524",
    "saved_at": "2025-10-24T07:47:49.284509+00:00",
    "goal": "Extract evidence on real-world implementation challenges: payer policies, access restrictions, patient eligibility criteria, provider prescribing patterns, and barriers to optimal use. Identify specific gaps between clinical trial populations and real-world users.",
    "raw_file": null,
    "extracted_file": null,
    "summary_file": null,
    "status": "fallback",
    "http_status": null,
    "content_type": null,
    "final_url": "https://www.sciencedirect.com/science/article/pii/S2213176724000524"
  }
]